Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Cell Origins of High-Grade Serous Ovarian Cancer.

Kim J, Park EY, Kim O, Schilder JM, Coffey DM, Cho CH, Bast RC Jr.

Cancers (Basel). 2018 Nov 12;10(11). pii: E433. doi: 10.3390/cancers10110433. Review.

2.

Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.

Tew WP, Sill MW, Walker JL, Secord AA, Bonebrake AJ, Schilder JM, Stuckey A, Rice L, Tewari KS, Aghajanian CA.

Gynecol Oncol. 2018 Nov;151(2):257-263. doi: 10.1016/j.ygyno.2018.08.027. Epub 2018 Aug 31.

PMID:
30177462
3.

Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

Monk BJ, Sill MW, Walker JL, Darus CJ, Sutton G, Tewari KS, Martin LP, Schilder JM, Coleman RL, Balkissoon J, Aghajanian C.

J Clin Oncol. 2016 Jul 1;34(19):2279-86. doi: 10.1200/JCO.2015.65.8153. Epub 2016 May 23.

4.

A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.

Bender D, Sill MW, Lankes HA, Reyes HD, Darus CJ, Delmore JE, Rotmensch J, Gray HJ, Mannel RS, Schilder JM, Hunter MI, McCourt CK, Samuelson MI, Leslie KK.

Gynecol Oncol. 2015 Sep;138(3):507-12. doi: 10.1016/j.ygyno.2015.07.018. Epub 2015 Jul 15.

5.

A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.

Dizon DS, Sill MW, Schilder JM, McGonigle KF, Rahman Z, Miller DS, Mutch DG, Leslie KK.

Gynecol Oncol. 2014 Dec;135(3):441-5. doi: 10.1016/j.ygyno.2014.10.001. Epub 2014 Oct 13.

6.

Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.

Alvarez EA, Brady WE, Walker JL, Rotmensch J, Zhou XC, Kendrick JE, Yamada SD, Schilder JM, Cohn DE, Harrison CR, Moore KN, Aghajanian C.

Gynecol Oncol. 2013 Apr;129(1):22-7. doi: 10.1016/j.ygyno.2012.12.022. Epub 2012 Dec 20.

PMID:
23262204
7.

Identification of the optimal pathway to reach an accurate diagnosis in the absence of an early detection strategy for ovarian cancer.

Hess LM, Stehman FB, Method MW, Weathers TD, Gupta P, Schilder JM.

Gynecol Oncol. 2012 Dec;127(3):564-8. doi: 10.1016/j.ygyno.2012.08.029. Epub 2012 Aug 30.

PMID:
22940492
8.

The Morphology Index: predictive value of malignancy among clinicians at various levels of training.

Barnsfather K, Fitzpatrick CB, Wilson J, Linn CL, Brizendine E, Schilder JM.

Gynecol Oncol. 2012 Oct;127(1):94-7. doi: 10.1016/j.ygyno.2012.06.043. Epub 2012 Jul 6.

PMID:
22776722
9.

Elevated and secreted phospholipase A₂ activities as new potential therapeutic targets in human epithelial ovarian cancer.

Cai Q, Zhao Z, Antalis C, Yan L, Del Priore G, Hamed AH, Stehman FB, Schilder JM, Xu Y.

FASEB J. 2012 Aug;26(8):3306-20. doi: 10.1096/fj.12-207597. Epub 2012 Jul 5.

10.

Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group.

Kunos CA, Sill MW, Buekers TE, Walker JL, Schilder JM, Yamada SD, Waggoner SE, Mohiuddin M, Fracasso PM.

Gynecol Oncol. 2011 Feb;120(2):224-8. doi: 10.1016/j.ygyno.2010.10.018.

11.

A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study.

Fiorica JV, Blessing JA, Puneky LV, Secord AA, Hoffman JS, Yamada SD, Buekers TE, Bell J, Schilder JM; Gynecologic Oncology Group.

Gynecol Oncol. 2009 Nov;115(2):285-9. doi: 10.1016/j.ygyno.2009.07.024. Epub 2009 Sep 2.

PMID:
19726073
12.

Identification and characterization of ovarian cancer-initiating cells from primary human tumors.

Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP.

Cancer Res. 2008 Jun 1;68(11):4311-20. doi: 10.1158/0008-5472.CAN-08-0364.

13.

A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study.

Armstrong DK, Bookman MA, McGuire W, Bristow RE, Schilder JM; Gynecologic Oncology Group.

Gynecol Oncol. 2007 Jun;105(3):667-71. Epub 2007 Mar 21.

14.

Stage Ia-IIa cancer of the cervix.

Schilder JM, Stehman FB.

Cancer J. 2003 Sep-Oct;9(5):395-403. Review.

PMID:
14690315
15.

Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy.

Schilder JM, Thompson AM, DePriest PD, Ueland FR, Cibull ML, Kryscio RJ, Modesitt SC, Lu KH, Geisler JP, Higgins RV, Magtibay PM, Cohn DE, Powell MA, Chu C, Stehman FB, van Nagell J.

Gynecol Oncol. 2002 Oct;87(1):1-7.

PMID:
12468335
16.

"What's in a name? That which we call a rose, by any other name.".

Stehman FB, Schilder JM.

Obstet Gynecol. 2002 Dec;100(6):1146-7. No abstract available.

PMID:
12468156

Supplemental Content

Loading ...
Support Center